LUCENCE


Associated tags: Liquid biopsy, Patient, CLIA, Oncology, Health, Biotechnology, Medical imaging, Medical Devices, Lung cancer, Hospitals, Pharmaceutical, Gene, Research, Cancer, Medicine, Mutation, NSCLC, MBBS, Doctor of Philosophy, Neoplasm

Locations: US, HONG KONG, CALIFORNIA, SINGAPORE, UNITED STATES, NORTH AMERICA, ASIA PACIFIC

Lucence Launches LucenceINSIGHT to Detect Cancer Earlier

Retrieved on: 
Wednesday, May 10, 2023
Oncology, Medical Devices, Health, Research, Science, Biotechnology, Agency for Science, Technology and Research, Medicine, National Research Foundation (South Africa), Enterprise Singapore, Ageing, Cancer, National Research Foundation, NRF, Medicare, DPM, Laboratory, Growth, Group Policy, Medtech, SME, Mobile phone, Film industry

Asia’s aging population is confronted with a growing cancer crisis, with nearly 10 million new cancer cases annually.

Key Points: 
  • Asia’s aging population is confronted with a growing cancer crisis, with nearly 10 million new cancer cases annually.
  • Early cancer detection when it is most treatable can prevent unnecessary cancer deaths.
  • Lucence is launching LucenceINSIGHT™, an MCED test first internationally and with a follow-up U.S. launch in Q3 2023.
  • Our mission is early cancer detection through a single blood test, when cancer is most treatable hopefully for cure.

Lucence Announces Medicare Reimbursement Decision for LiquidHALLMARK® Assay in Lung Cancer

Retrieved on: 
Wednesday, February 22, 2023
Other Health, Research, General Health, Professional Services, Pharmaceutical, Oncology, Medical Devices, Hospitals, Data Analytics, Science, Biotechnology, Health, NGS, Policy, Metastasis, International Society, Form 1095, Biomarker, FDA, Patient, LCD, Lung cancer, Medicare, NSCLC, NCCN, Medical imaging

The LCD covers all nine NCCN guideline-recommended molecular biomarkers in advanced lung cancer patients using LiquidHALLMARK.

Key Points: 
  • The LCD covers all nine NCCN guideline-recommended molecular biomarkers in advanced lung cancer patients using LiquidHALLMARK.
  • LiquidHALLMARK is Lucence’s next-generation sequencing (NGS) liquid biopsy test, which helps oncologists identify biomarkers in advanced cancer patients that may inform their treatment decisions.
  • The policy provides for Medicare reimbursement for LiquidHALLMARK tests furnished to most Medicare fee-for-service patients with lung cancer who meet clinical criteria.
  • Dr Min-Han Tan, Founding CEO, remarked on the significance of this milestone, saying, “Over 150,000 lung cancer patients over the age of 65 are diagnosed every year in the United States.

Lucence Presents Data at 2022 World Conference on Lung Cancer (WCLC) Supporting Utility of Amplicon-Based Liquid Biopsy From Detection Through Treatment

Retrieved on: 
Wednesday, July 13, 2022
Biotechnology, Pharmaceutical, Health, Oncology, Lung, NGS, BRCA, Conference, Gene, EGFR, Abstract (summary), Mutation, Medicine, NSCLC, Biomarker, CLIA, Patient, Neoplasm, Large-cell lung carcinoma, PLOS ONE, Plasma, Somatic mutation, CtRNA, Lung cancer, PLOS, TCR, Nucleic acid thermodynamics, VAF, Liquid biopsy, Medical imaging

Lucence will present new data at the upcoming IASLC 2022 World Conference on Lung Cancer on August 6-9, 2022, highlighting novel applications of its ultrasensitive amplicon-based next generation sequencing technology in the detection and treatment of lung cancer.

Key Points: 
  • Lucence will present new data at the upcoming IASLC 2022 World Conference on Lung Cancer on August 6-9, 2022, highlighting novel applications of its ultrasensitive amplicon-based next generation sequencing technology in the detection and treatment of lung cancer.
  • Liquid biopsy will continue to transform the way we diagnose, treat, and understand lung cancer, said Min-Han Tan, Founding CEO and Medical Director at Lucence.
  • Abstracts to be presented in poster presentations at the conference build on Lucences continued innovation in liquid biopsy in the detection, treatment, and monitoring of lung cancer.
  • 14.3% additional lung cancer cases were detected compared to ctDNA detection alone, demonstrating the utility of a multi-signal cfDNA approach for sensitive detection of lung cancer.

Lucence Showcases Promising Data on ctDNA and ctRNA Liquid Biopsy Assay for Lung Cancer at 2022 ASCO Annual Meeting

Retrieved on: 
Tuesday, May 31, 2022
Research, Medical Devices, Hospitals, Other Health, Biotechnology, General Health, Pharmaceutical, Health, Science, Oncology, DNA, NGS, Gene, Doctor of Philosophy, Patient, MBBS, Health, Lung cancer, Society, PARP, BRAF, Circulating tumor DNA, Tyrosine, CtRNA, Plasma, MET, RNA, Liquid biopsy, ASCO, Large-cell lung carcinoma, NRG1, CLIA, LOH, Mutation, HRD, Chowdhury, Medical imaging, NSCLC, Neoplasm

Lucence strives to provide clinicians with the most clinically actionable information to impact patient care using liquid biopsy.

Key Points: 
  • Lucence strives to provide clinicians with the most clinically actionable information to impact patient care using liquid biopsy.
  • The data we are presenting at 2022 ASCO shows how a total nucleic acid approach combining ctDNA and ctRNA in one liquid biopsy assay could dramatically increase actionable molecular information in lung cancer patients, said Min-Han Tan, PhD, MBBS, Founding CEO of Lucence.
  • In plasma samples from non-small cell lung cancer (NSCLC) patients that were either baseline driver-negative (by ctDNA) or treated with tyrosine kinase-inhibitors, the combined assay found 8.7% (9/103) more actionable fusions than ctDNA alone.
  • The data support combining ctRNA with ctDNA in liquid biopsy to increase the total actionable diagnostic information in NSCLC patients where tissue samples are lacking, especially for gene fusions not amenable to detection in ctDNA.

Lucence Announces Publication of Validation Study for LiquidHALLMARK ctDNA Liquid Biopsy Assay

Retrieved on: 
Thursday, May 19, 2022
Research, Medical Devices, Hospitals, Other Health, Biotechnology, General Health, Pharmaceutical, Health, Science, Oncology, Senior, Physician, Company, PLOS, Gene, Medicine, Patient, Woman, NCI, AMAG Pharmaceuticals, Lung cancer, Clinical trial, Oncology, Â, Health care, FDA, LabCorp, CtRNA, Chief commercial officer, Commercial, Marketing, Reproduction, Biomarker, Liquid biopsy, PCR, VAF, EGFR, CLIA, Mutation, Cancer, Neoplasm, Medical imaging, Vaccine, Management

Lucence, the precision oncology company pioneering ultrasensitive liquid biopsy tests, is announcing the recent publication of a study validating its LiquidHALLMARK ctDNA liquid biopsy assay in PLOS ONE , a peer-reviewed, open access scientific journal.

Key Points: 
  • Lucence, the precision oncology company pioneering ultrasensitive liquid biopsy tests, is announcing the recent publication of a study validating its LiquidHALLMARK ctDNA liquid biopsy assay in PLOS ONE , a peer-reviewed, open access scientific journal.
  • Lucence continues to build scientific and commercial momentum, and this recent publication follows several notable company milestones, including the announcement of its combined ctDNA + ctRNA assay .
  • Lucences LiquidHALLMARK ctDNA liquid biopsy assay covers a wide range of clinically relevant cancer biomarkers, including mutations in 80 genes in 15 cancer types.
  • LiquidHALLMARK ctDNA and ctRNA combines ctRNA profiling of 27 actionable and emerging fusions with ctDNA profiling for enhanced fusion detection.

Lucence’s LiquidHALLMARK Liquid Biopsy Assay Expands to Include cfRNA

Retrieved on: 
Monday, January 10, 2022
Radiology, Biotechnology, Oncology, Health, Medical Devices, Hospitals, Genetics, Clinical Trials, Biomarker, Patient, MBBS, University, NRG, NRG1, RNA, COVID-19, Severe acute respiratory syndrome coronavirus 2, CLIA, Medical director, Gene, Oncology, Plasma, CFRNA, TRK, DNA, NCI, Liquid biopsy, NSCLC, Doctor of Philosophy, Cancer, Mutation, Nucleic acid thermodynamics, Physician, Large-cell lung carcinoma, COVID, Vaccine

Lucence, a precision oncology company using liquid biopsy to bring clarity to cancer care, is announcing the availability of an expanded version of its flagship LiquidHALLMARK liquid biopsy assay that includes both cell-free DNA (cfDNA) and cell-free RNA (cfRNA) profiling.

Key Points: 
  • Lucence, a precision oncology company using liquid biopsy to bring clarity to cancer care, is announcing the availability of an expanded version of its flagship LiquidHALLMARK liquid biopsy assay that includes both cell-free DNA (cfDNA) and cell-free RNA (cfRNA) profiling.
  • Including cfRNA in a liquid biopsy assay has a significant impact on the detection of clinically relevant fusions.
  • Lucences LiquidHALLMARK cfDNA and cfRNA panel combines cfRNA profiling of 27 actionable and emerging fusions with cfDNA profiling of mutations in 80 genes, fusions in 10 genes, and somatic variants in 15 cancer types.
  • Lucence makes ultrasensitive liquid biopsy tests to provide doctors and their patients life-changing information to enable earlier detection and effective treatment.

Lucence Launches First Liquid Biopsy Screening Study in Partnership with the VA Palo Alto Health Care System

Retrieved on: 
Thursday, November 11, 2021
Oncology, Health, Hospitals, Clinical Trials, Radiology, Biotechnology, Mortality, Bed, Pacific Ocean, VA Palo Alto Health Care System, Lung cancer, Cancer, Associate, Observational study, Nursing, CLIA, MD, Disease, Doctor of Philosophy, Technology, Oncology, Liquid biopsy, MBBS, United, Interventional radiology, Community, Clinic, DNA methylation, Partnership, Neoplasm, Stanford University, Detection, Radiology, Physician, DNA, Principal investigator, PET/CT, Bronchoscopy, Medical imaging, Lucence, VA Palo Alto Health Care System, LUCENCE, VA PALO ALTO HEALTH CARE SYSTEM

In partnership with the VA Palo Alto Health Care System, precision oncology company Lucence is launching its first early detection study in the United States evaluating the use of its liquid biopsy technology in a screening context.

Key Points: 
  • In partnership with the VA Palo Alto Health Care System, precision oncology company Lucence is launching its first early detection study in the United States evaluating the use of its liquid biopsy technology in a screening context.
  • We are proud to be partnering with Dr. Shah and the VA Palo Alto to serve such an important population.
  • Headquartered in Palo Alto, Lucence supplies personalized cancer care services through twin CLIA-licensed laboratories in the United States and Singapore.
  • VA Palo Alto Health Care System (VAPAHCS) is part of VA Sierra Pacific Network (VISN 21), which serves Veterans in northern and central California, Nevada, Hawaii, the Philippines, and U.S.

Lucence and Yemaachi Launch the AMBER Study to Detect and Characterize Genomic Alterations in Breast Cancer in Women in Africa and Expand Liquid Biopsy Access

Retrieved on: 
Tuesday, October 26, 2021
Biotechnology, General Health, Health, Pharmaceutical, Oncology, Breast cancer, Cancer, Amber Marchese, Research, PIK3CA, ESR1, Gene, Genomics, CLIA, BRCA1, Patient, BRCA2, Y Combinator, AMBER, Liquid biopsy, Detection, MBBS, Medicine, Nucleic acid thermodynamics, CEO, Multimedia, Artificial intelligence, Population, Doctor of Philosophy, Oncology, Medical imaging, Lucence, Yemaachi, LUCENCE, YEMAACHI

Lack of access to next-generation sequencing technologies is a critical component of existing disparities in oncology.

Key Points: 
  • Lack of access to next-generation sequencing technologies is a critical component of existing disparities in oncology.
  • Breast cancer is the most common cancer in women, responsible for almost a third of all cancers in Africa, and the leading cause of cancer-related mortality in Ghanaian women.
  • We are excited to partner with Yemaachi on this important work, said Min-Han Tan, MBBS, PhD, Founding CEO of Lucence.
  • Lucence makes ultrasensitive liquid biopsy tests to provide doctors and their patients life-changing information to enable earlier detection and effective treatment.

Lucence Presents Data at ESMO 2021 Showing Liquid Biopsy Detects Actionable Genomic Alterations in Bladder Cancer Patients Undergoing Immunotherapy

Retrieved on: 
Monday, September 13, 2021
Oncology, Health, Genetics, Research, Science, Pharmaceutical, Biotechnology

Precision oncology company Lucence, in collaboration with researchers at Dana-Farber Cancer Institute and Brigham and Womens Hospital, is sharing data highlighting the capabilities of its amplicon-based liquid biopsy technology to detect and characterize genomic alterations in ctDNA in patients with late-stage bladder cancer undergoing immunotherapy.

Key Points: 
  • Precision oncology company Lucence, in collaboration with researchers at Dana-Farber Cancer Institute and Brigham and Womens Hospital, is sharing data highlighting the capabilities of its amplicon-based liquid biopsy technology to detect and characterize genomic alterations in ctDNA in patients with late-stage bladder cancer undergoing immunotherapy.
  • The data will be presented as part of a virtual poster presentation at the European Society for Medical Oncology (ESMO) Congress 2021.
  • Most mUC patients do not respond, or develop resistance to, ICI and obtaining tissue biopsies before and throughout treatment is invasive and presents risks of complications.
  • Lucence makes ultrasensitive liquid biopsy tests to provide doctors and their patients life-changing information to enable earlier detection and effective treatment.

Lucence Presents Real-World Evidence on Applications of Liquid Biopsy at 2021 ASCO, Announces Formation of Medical Advisory Board

Retrieved on: 
Wednesday, June 2, 2021
Biotechnology, Health, Oncology, Clinical trials

As part of the 2021 ASCO Annual Meeting, precision oncology company Lucence is sharing real-world data supporting clinical applications of its amplicon-based liquid biopsy assay.

Key Points: 
  • As part of the 2021 ASCO Annual Meeting, precision oncology company Lucence is sharing real-world data supporting clinical applications of its amplicon-based liquid biopsy assay.
  • Lucence is also announcing the formation of a medical advisory board in the United States.
  • Lucences Medical Advisory Board will be tasked with providing strategic, patient-centered guidance on research, development, and clinical applications of amplicon-based liquid biopsy tests.
  • Lucence makes ultrasensitive liquid biopsy tests to provide doctors and their patients life-changing information to enable earlier detection and effective treatment.